Flex Pharma demonstrates efficacy of synthesized single and combination agents in reducing human muscle cramps

Presentation at the European Committee for Treatment and Research of Multiple Sclerosis

The abstract titled, “TRPV1 and TRPA1 activators reduce muscle cramping: Potential new treatment for MS symptoms,” will be presented by neurologist and Flex Pharma Chief Medical Officer, Dr Tom Wessel, who served as the medical lead for three products approved in US: Razadyne, Lunesta and Ampyra.

“By testing the most potent TRPA1 and TRPV1 agonists and demonstrating enhanced efficacy with purified single agent and doublet combinations compared to the original proprietary formulation, we have made significant progress in our product development efforts,” said Dr Wessel. Utilizing the established electrically induced model in normal healthy volunteers (n=9), the purified single molecules, as well as combinations of two individual molecules, of GMP-synthesized TRPA1 and TRPV1 agonists, significantly reduced cramp intensity relative to vehicle control (p<0.01) and compared to the original proprietary formulation of extract mixture (p<0.05).

Nobel laureate and Flex Pharma Scientific Co-Founder and Scientific Advisory Board Co-Chair, Dr Rod MacKinnon noted: “We are excited to be on the forefront of investigating chemical neuro stimulation as a novel and perhaps generally applicable method to treat disorders of cramping and spasms stemming from alpha motor neuron hyperexcitability.”